[PROTOCOL CPT-MD-32] A MULTICENTER, 2-COHORT STUDY TO DESCRIBE THE SAFETY AND EFFICACY OF CEFTAROLINE FOSAMIL IN SUBJECTS WITH STAPHYLOCOCCUS AUREUS BACTERMEMIA OR WITH PERSISTANT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS BACTEREMIA

Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia

Approval Date: 12/10/2012

Principal Investigator: Matthew D. Sims, MD PhD

The purpose of this study is to evaluate the safety and effectiveness of a new drug in patients who have Staphylococcus aureus Bacteremia or with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia that continues even after at least 72 hours of antibiotic (vancomycin or daptomycin) treatment.

Eligibility:

Every study has inclusion and exclusion criteria that determine who is able to participate in the study. The study PI will evaluate if you meet these criteria. More information may be found here on clinicaltrials.gov.

Contact Person:
Ashish Solanki
248-995-0197

Status of Clinical Trial:
open and enrolling